CLAIMS

1. Use of a therapeutically effective amount of niraparib in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of abiraterone acetate, and a therapeutically effective amount of prednisone.

2. Use of a therapeutically effective amount of abiraterone acetate in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of niraparib, and a therapeutically effective amount of prednisone.

3. Use of a therapeutically effective amount of prednisone in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of abiraterone acetate, and a therapeutically effective amount of niraparib.

4. Use of a therapeutically effective amount of abiraterone acetate and a therapeutically effective amount of niraparib in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of prednisone.

5. Use of a therapeutically effective amount of abiraterone acetate and a therapeutically effective amount of prednisone in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of niraparib.

6. Use of a therapeutically effective amount of niraparib and a therapeutically effective amount of prednisone in the manufacture of a medicament for the treatment of a prostate cancer which is to be administered to a patient in need thereof, together with a therapeutically effective amount of niraparib.

7. Use of a therapeutically effective amount of abiraterone acetate, a therapeutically effective amount of prednisone, and a therapeutically effective amount of niraparib in the manufacture of a medicament for the treatment of a prostate cancer.

8. The use according to any one of the preceding claims, wherein the prostate cancer is hormone-sensitive or castration-resistant prostate cancer.

9. The use according to any one of claims 1 to 3 or claim 5 or claim 6, wherein niraparib and abiraterone acetate, are to be administered to the patient in a single composition.

10. The use according to any one of claims 1 to 3 or claim 5 or claim 6, wherein niraparib is to be administered in a separate composition from abiraterone acetate.

11. The use according to any one of the preceding claims , wherein niraparib and abiraterone acetate are each to be administered once daily to the patient.

12. The use according to any one of claims 1 to 3 or claim 5 or claim 6, wherein niraparib is to be administered in a separate composition from the abiraterone acetate and prednisone.

13. The use according to any one of claims 1 to 3, wherein niraparib, abiraterone acetate, and prednisone are each to be administered in separate compositions.

14. The use according to any one of the preceding claims, wherein about 500 to about 1500 mg/day of the abiraterone acetate is to be administered to the patient.

15. The use according to claim 14, wherein about 600 to about 1300 mg/day of the abiraterone acetate is to be administered to the patient.

16. The use according to claim 15 wherein about 900 to about 1100 mg/day of the abiraterone acetate is to be administered to the patient.

17. The use according to claim 16, wherein about 1000

mg/day of the abiraterone acetate is to be administered to the patient.

18. The use according to claim 17, wherein about 500 mg/day of the abiraterone acetate is to be administered to the patient.

19. The use according to claim 14, wherein about 30 to about 400 mg/day of the niraparib is to be administered to the patient.

20. The use according to claim 19, wherein about 100 to about 300 mg/day of the niraparib is to be administered to the patient.

21. The use according claim 20, wherein about 175 to about 225 mg/day of the niraparib is to be administered to the patient.

22. The use according to claim 17, wherein about 200 mg/day of the niraparib is to be administered to the patient.

23. The use according to claim 18, wherein about 200 mg/day of the niraparib is to be administered to the patient.

24. The use according to claim 19, wherein about 1 to about 25 mg/day of the prednisone is to be administered to the patient.

25. The use according to claim 20, wherein about 5 to about 15 mg/day of the prednisone is to be administered to the patient.

26. The use according to claim 21, wherein about 9 to about 11 mg/day of the prednisone is to be administered to the patient.

27. The use according to claim 22, wherein about 10 mg/day of the prednisone is to be administered to the patient.

28. The use according to claim 23, wherein about 10mg/day of the prednisone is to be administered to the patient.

29. The use according to claim 22, wherein about 5 mg/day of the prednisone is to be administered to the patient.

30. The use according to claim 23, wherein about 5 mg/day of the prednisone is to be administered to the patient.

31. The use according to any one of the preceding claims, wherein the niraparib and the abiraterone acetate is/are to be administered to the patient once per day over multiple days, and increasing the dosage of one or both of the niraparib and abiraterone acetate at least once over time.

32. The use according to claim 11 wherein the dosing of niraparib is increased at least once over time.

33. The use according to claim 31, wherein the prednisone is to be administered to the patient twice per day over multiple days, and increasing the dosage of the prednisone at least once over time.

34. The use according to any one of the receding claims 1, wherein the niraparib, the abiraterone acetate, and the prednisone are to be administered to the patient orally.

35. The use according to any one of the preceding claims, wherein the patient underwent taxane-based chemotherapy prior to the administration of a first dose of the niraparib and the abiraterone acetate.

36. The use according to claim 1, wherein the patient underwent at least one line of androgen receptor-targeted therapy prior to the administration of a first dose of the niraparib and the abiraterone acetate

37. A pharmaceutical composition comprising niraparib, abiraterone acetate, and prednisone in a total amount that is in a single oral dosage form therapeutically effective for the treatment of prostate cancer in a human patient.

38. The composition according to claim 37, wherein said composition is configured for oral administration.

39. The composition according to claim 37 or claim 38 wherein the composition comprises about 100 to about 350 mg of the niraparib, about 100 to about 1500 mg of the abiraterone acetate, and about 2 to about 15 mg of the prednisone.

40. A pharmaceutical composition comprising niraparib, abiraterone acetate, and prednisone in a total amount that is in multiple oral dosage forms therapeutically effective for the treatment of prostate cancer in a human patient.

41. The composition according to claim 40, wherein said composition is configured for oral administration.

42. The composition according to claim 40 or claim 41, wherein the composition comprises about 100 to about 350 mg of the niraparib, about 100 to about 1500 mg of the abiraterone acetate, and about 2 to about 15 mg of the prednisone.